Laboratory of Kidney Transplantation and Renal Replacement Therapy












            ******************************************************************************************

            *
            ******************************************************************************************




            ******************************************************************************************

            * Offer
            ******************************************************************************************
            - Suggestion of desing a methods of clinical studies in the field of viral infections afte

            transplantation, biocompatibility of dialysis membranes and peritoneal dialysis solutions,
            therapy during hemodialysis, and infectious

            complications in hemodialysis population
            - Evaluation of biocompatibility of dialysis membranes
            - Cytomegalovirus and polyomavirus detection in blood or other tissues bas on molecular bi

            - Assessment of cytomegalovirus antiviral drug resistance





            ******************************************************************************************

            * Expertise
            ******************************************************************************************
            - Research activity is focused on infectious complications and their association with long

            kidney transplantation, and mainly with the incidence of graft rejection
            - In a long run optimal mode of cytomegalovirus prevention has been evaluated in independe
            trials with results being incorporated to the International Guidelines

            - The possibilities of improvement of biocompatibility and anticoagulation therapy during 
            assessed in patients with end-stage kidney disease






            ******************************************************************************************
            * Members
            ******************************************************************************************

            - Assoc. Prof. Tomáš Reischig, M.D., Ph.D. – Research Group Leader
            - Mirko Bouda, M.D.
            - Kateřina Černá, M.D., Ph.D.

            - Assoc. Prof. Jaromír Eiselt, M.D., Ph.D.
            - Prof. Ondřej Hes, M.D., Ph.D.
            - Pavel Jindra, M.D., Ph.D.

            - Martin Kačer, M.D., Ph.D.
            - Lenka Karlíková, B.Sc.
            - Lukáš Kielberger, M.D., Ph.D.

            - Jan Klaboch, M.D., Ph.D.
            - Jana Němcová, M.Sc., Ph.D.
            - Ondrej Ondič, M.D.

            - Prof. Sylvie Opatrná, M.D., Ph.D.
            - Irena Prýcová
            - Pavlína Richtrová, M.D., Ph.D.

            - Prof. Tomáš Seeman, M.D., Ph.D.
            - Daniela Šantová
            - Tomáš Vaněček, Ph.D., M.Sc.

            - Prof. Ondřej Viklický, M.D., Ph.D.
            - Tomáš Vlas, M.Sc.
            - Silvie Vondráková






            ******************************************************************************************
            * Selected Publications

            ******************************************************************************************
            - Reischig T, Hribova P, Jindra P, Hes O, Bouda M, Treska V, Viklicky O.: Pre-emptive valg
            therapy compared with valacyclovir prophylaxis for prevention of cytomegalovirus: 4-year r

            randomized trial in renal transplant recipients. J Am Soc Nephrol 2012, 23 (9): 1588–97
            - Reischig T., Jindra P., Hes O., Bouda M., Kormunda S., Treska V.: Effect of cytomegalovi
            subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3

            allograft recipients managed by preemptive therapy or antiviral prophylaxis. Transplantati
            436–444
            - Reischig T, Prucha M, Sedlackova L, Lysak D, Jindra P, Bouda M, Matejovic M.: Valgancicl

            against cytomegalovirus impairs lymphocyte proliferation and activation in renal transplan
            Antivir Ther 2011, 16: 1227–1235
            - Richtrova P, Rulcova K, Mares J, Reischig T.: Evaluation of three different methods to p

            clotting without causing systemic anticoagulation effect. Artif Organs 2011, 35 (1): 83–88
            - Reischig T.: Advances in cytomegalovirus-preventive strategies in solid organ transplant
            pre-emptive therapy. Expert Rev Anti Infect Ther 2012, 10: 51–61

            - Reischig T, Kacer M, Jindra P, Hes O, Lysak D, Bouda M.: Randomized trial of valganciclo
            valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation. Clin 
            2015, 15 (2): 294–304






            ******************************************************************************************
            * Are you interested in this expertise?

            ******************************************************************************************
            Please contact CPPT UK
            Web: www.cppt.cuni.cz/ [ URL "https://cppt.cuni.cz/"]

            Mail: transfer@cuni.cz
            Phone: +420 224 491 255






            ******************************************************************************************
            * Experts and their department
            ******************************************************************************************

            Assoc. Prof. Tomáš Reischig, M.D., Ph.D.
            Biomedical Center
            Web: http://www.biomedic-plzen.cz/cz [ URL "http://www.biomedic-plzen.cz/cz"]